EQUITY RESEARCH MEMO

Waddell Group

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)60/100

Waddell Group is a US-based consulting firm specializing in medical device and drug delivery project management. Since its founding in 2008, the company has successfully delivered over 600 projects, offering expertise in regulatory strategy, manufacturing, process engineering, and M&A integration. Led by a team of experienced project executives, Waddell Group helps clients navigate the complex development-to-market lifecycle, reducing time and cost while ensuring compliance. As a private services company with a strong track record, it is well-positioned to benefit from ongoing innovation in medtech and pharmaceutical outsourcing trends. However, its growth is inherently tied to the broader industry cycle and client spending.

Upcoming Catalysts (preview)

  • Q3 2026Expansion of Regulatory Consulting Services Amid FDA Reforms75% success
  • Q4 2026Strategic Partnership with a Major Medtech OEM for Project Management Outsourcing40% success
  • Q1 2027Launch of Specialized Digital Health Consulting Practice50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)